In 2022, Yoon et al. conducted a study which showed that using the CRISPR-Cas9 system to delete the A53T-SNCA gene significantly improved conditions related to Parkinson's disease, such as the overproduction of α-synuclein, reactive microgliosis, dopaminergic neurodegeneration, and motor symptoms associated with Parkinson's (Yoon et al., 2022[109]). The gene discussed is SNCA; the disease is Parkinson disease.